JANX

Janux Therapeutics, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $16.93
52-Week Range: $12.12 – $35.34
Market Cap: $1.01B
P/E (TTM): —
EPS (TTM): -1.64
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.09
PEG Ratio: —
Return on Equity: -10.70%
Return on Assets: -8.80%
Gross Margin: 0.00%
Operating Margin: -308.66%
Profit Margin: 0.00%
Current Ratio: 16.35
Debt/Equity: 0.02
Total Debt: $20.99M
Free Cash Flow: $-16.39M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $85.12M

JANX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$8.61M	$8.08M	$10.59M	$10.00M
Research & Development	$53.44M	$54.92M	$68.39M	$125.90M
Selling, General & Admin	$22.26M	$26.14M	$41.05M	$41.77M
Operating Expenses	$75.70M	$81.06M	$109.44M	$167.67M
Operating Income	-$67.09M	-$72.98M	-$98.85M	-$157.67M
EBITDA	-$66.25M	-$71.02M	-$96.79M	-$155.64M
Pretax Income	-$63.06M	-$58.29M	-$68.99M	-$113.63M
Net Income	-$63.06M	-$58.29M	-$68.99M	-$113.63M
Diluted EPS	-1.52	-1.32	-1.28	-1.83
Diluted Shares	41.47M	44.02M	53.75M	61.97M

JANX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$51.43M	$19.20M	$430.61M	$52.33M
Receivables	—	$2.16M	$5.38M	$6.43M
Current Assets	$332.44M	$349.24M	$1.03B	$975.89M
Total Assets	$364.01M	$380.41M	$1.06B	$1.00B
Current Liabilities	$16.51M	$13.03M	$17.46M	$25.00M
Total Debt	$25.30M	$24.54M	$23.02M	$22.14M
Total Liabilities	$43.27M	$36.06M	$38.73M	$44.74M
Retained Earnings	-$110.47M	-$168.76M	-$237.76M	-$351.38M
Shareholders' Equity	$320.74M	$344.35M	$1.02B	$956.82M
Working Capital	$315.93M	$336.21M	$1.02B	$950.89M

JANX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$42.92M	-$50.58M	-$43.81M	-$82.23M
Capital Expenditure	-$6.45M	-$1.85M	-$359.00K	-$1.04M
Free Cash Flow	-$49.37M	-$52.42M	-$44.17M	-$83.28M
Depreciation & Amortisation	$841.00K	$1.96M	$2.06M	$2.03M
Stock-Based Compensation	$17.20M	$20.00M	$33.02M	$40.22M
Investing Cash Flow	$58.27M	-$41.19M	-$258.02M	-$300.98M
Financing Cash Flow	$500.00K	$59.55M	$713.24M	$4.95M
Share Repurchases	—	—	—	-$347.00K
Net Change in Cash	$15.84M	-$32.22M	$411.40M	-$378.27M

JANX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$10.00M	$0.00	$3.73M	$10.27M
Research & Development	$25.05M	$34.66M	$34.63M	$31.55M	$26.81M	$30.99M
Selling, General & Admin	$9.84M	$10.45M	$10.62M	$10.85M	$11.13M	$10.96M
Operating Expenses	$34.90M	$45.12M	$45.25M	$42.40M	$37.95M	$41.96M
Operating Income	-$34.90M	-$45.12M	-$35.25M	-$42.40M	-$34.21M	-$31.69M
EBITDA	-$34.38M	-$44.58M	-$34.75M	-$41.93M	-$33.74M	-$31.23M
Pretax Income	-$23.51M	-$33.86M	-$24.31M	-$31.95M	-$24.36M	-$21.97M
Net Income	-$23.51M	-$33.86M	-$24.31M	-$31.95M	-$24.36M	-$21.97M
Diluted EPS	-0.38	-0.55	-0.39	-0.51	-0.39	-0.35
Diluted Shares	61.79M	61.90M	62.02M	62.15M	62.67M	62.94M

JANX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$73.74M	$52.45M	$48.39M	$52.33M	$51.83M	$27.77M
Receivables	$5.58M	$5.69M	$6.32M	$6.43M	$42.46M	$6.33M
Current Assets	$1.02B	$1.01B	$998.09M	$975.89M	$1.00B	$983.34M
Total Assets	$1.05B	$1.03B	$1.02B	$1.00B	$1.03B	$1.01B
Current Liabilities	$17.50M	$21.38M	$27.83M	$25.00M	$58.91M	$60.15M
Total Debt	$22.61M	$22.19M	$22.66M	$22.14M	$21.57M	$20.99M
Total Liabilities	$38.30M	$41.70M	$48.21M	$44.74M	$86.69M	$79.67M
Retained Earnings	-$261.26M	-$295.12M	-$319.44M	-$351.38M	-$375.74M	-$397.71M
Shareholders' Equity	$1.01B	$990.52M	$976.55M	$956.82M	$941.53M	$927.98M
Working Capital	$1.01B	$984.17M	$970.25M	$950.89M	$943.13M	$923.18M

JANX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$17.02M	-$23.81M	-$12.86M	-$28.54M	-$12.34M	$12.48M
Capital Expenditure	-$371.00K	-$473.00K	-$93.00K	-$106.00K	-$273.00K	-$202.00K
Free Cash Flow	-$17.39M	-$24.29M	-$12.95M	-$28.65M	-$12.61M	$12.28M
Depreciation & Amortisation	$519.00K	$541.00K	$501.00K	$468.00K	$469.00K	$463.00K
Stock-Based Compensation	$10.70M	$10.96M	$9.04M	$9.52M	$9.27M	$9.06M
Investing Cash Flow	-$340.39M	$1.56M	$8.31M	$29.54M	$8.29M	-$38.78M
Financing Cash Flow	$554.00K	$954.00K	$493.00K	$2.94M	$3.54M	$2.24M
Share Repurchases	-$347.00K	$0.00	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	-$356.86M	-$21.30M	-$4.06M	$3.94M	-$506.00K	-$24.06M

Market Snapshot

About

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel T cell engager immunotherapies for the treatment of cancer. The company utilizes its proprietary Tumor Activated T Cell Engager (TRACTr) platform to create conditionally activated bispecific antibodies that selectively target tumor cells while sparing healthy tissue. Janux is advancing multiple product candidates through clinical development targeting solid tumors and hematologic malignancies. The company aims to improve the therapeutic window and reduce systemic toxicity compared to traditional T cell engagers.